|Bid||0.4510 x 900|
|Ask||0.4600 x 1300|
|Day's Range||0.4400 - 0.4695|
|52 Week Range||0.4200 - 2.4500|
|Beta (5Y Monthly)||2.07|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 08, 2022 - Nov 14, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||Dec 18, 2012|
|1y Target Est||5.60|
Christopher Ianelli, founder and CEO of iSpecimen, is leaving the company following a "mutual agreement" between him and the board of directors.
The FDA Oncologic Drugs Advisory Committee votes against Spectrum's (SPPI) poziotinib for treating non-small cell lung cancer in previously treated patients with HER2 exon 20 mutations. Stock down.
Yesterday, the FDA's Oncologic Drugs Advisory Committee (ODAC) panel voted against Spectrum Pharmaceuticals Inc's (NASDAQ: SPPI) poziotinib's (pozi) risk/benefit ratio and concluded that pozi's benefits do not outweigh the risks for the treatment of HER2 exon 20 insertion mutations. Meanwhile, with a newly approved commercial product Rolvedon launching into the $2.3 billion G-CSF space, JMP Securities believes that Spectrum shares still represent a unique investment opportunity with a 34% potent